Anavex Life Sciences (NASDAQ:AVXL) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Anavex Life Sciences (NASDAQ:AVXL) from a sell rating to a hold rating in a research note issued to investors on Saturday.

AVXL has been the subject of a number of other research reports. Jones Trading lowered shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anavex Life Sciences in a report on Monday, December 29th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Anavex Life Sciences in a report on Tuesday, February 10th. Finally, D. Boral Capital restated a “buy” rating and issued a $24.00 target price on shares of Anavex Life Sciences in a research note on Monday, February 9th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $22.00.

Anavex Life Sciences Price Performance

AVXL stock opened at $3.93 on Friday. The stock has a market capitalization of $364.19 million, a price-to-earnings ratio of -8.54 and a beta of 1.21. The company has a 50-day moving average of $4.26 and a two-hundred day moving average of $6.84. Anavex Life Sciences has a 52-week low of $2.86 and a 52-week high of $13.99.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.04. Equities analysts expect that Anavex Life Sciences will post -0.69 EPS for the current fiscal year.

Institutional Trading of Anavex Life Sciences

Several large investors have recently added to or reduced their stakes in the company. State Street Corp raised its position in Anavex Life Sciences by 33.4% in the 4th quarter. State Street Corp now owns 4,383,406 shares of the biotechnology company’s stock valued at $15,605,000 after purchasing an additional 1,096,288 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Anavex Life Sciences by 2.8% in the second quarter. Geode Capital Management LLC now owns 2,019,795 shares of the biotechnology company’s stock valued at $18,624,000 after buying an additional 54,985 shares during the last quarter. Two Sigma Investments LP lifted its position in Anavex Life Sciences by 6.5% during the 3rd quarter. Two Sigma Investments LP now owns 1,036,954 shares of the biotechnology company’s stock worth $9,229,000 after buying an additional 63,685 shares in the last quarter. Nwam LLC grew its holdings in Anavex Life Sciences by 2.4% during the 2nd quarter. Nwam LLC now owns 1,024,479 shares of the biotechnology company’s stock worth $9,446,000 after acquiring an additional 24,128 shares during the last quarter. Finally, Summit Financial LLC grew its holdings in Anavex Life Sciences by 103.3% during the 4th quarter. Summit Financial LLC now owns 903,392 shares of the biotechnology company’s stock worth $3,216,000 after acquiring an additional 459,121 shares during the last quarter. 31.55% of the stock is owned by institutional investors.

Key Headlines Impacting Anavex Life Sciences

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and raised near‑term and FY2026 EPS forecasts, signaling improved analyst confidence and a $20 target that could support upside. HC Wainwright Reiterates “Buy” Rating for Anavex Life Sciences (NASDAQ:AVXL)
• Positive Sentiment: HC Wainwright raised Q2–Q4 and FY2026 EPS estimates (e.g., Q4 from -$0.14 to -$0.11; FY from -$0.46 to -$0.33), suggesting expected operational or clinical progress that could improve future profitability. What is HC Wainwright’s Estimate for AVXL Q1 Earnings?
• Positive Sentiment: Zacks upgraded AVXL to a Rank #2 (Buy), reflecting growing optimism about the company’s earnings outlook and potentially attracting buy‑side interest. Anavex Life Sciences (AVXL) Upgraded to Buy
• Positive Sentiment: Anavex’s latest quarterly report beat EPS expectations (reported -$0.06 vs. consensus -$0.10), a near‑term fundamental positive that can support price momentum. MarketBeat AVXL profile
• Neutral Sentiment: Reports show a spike in short‑interest figures that are recorded as 0 shares and NaN changes — data appears erroneous or incomplete, so it’s unclear whether short covering or new shorts are influencing trading. (No reliable source link available.)
• Negative Sentiment: Despite upgrades, consensus still forecasts negative FY2026 EPS (-$0.69 before HC Wainwright adjustments), and the stock sits below both the 50‑day (~$4.27) and 200‑day (~$6.92) moving averages, indicating technical resistance and lingering macro/sector risk. MarketBeat AVXL profile

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.